EP Patent

EP0590793A1 — Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses

Assigned to Sankyo Co Ltd · Expires 1994-04-06 · 32y expired

What this patent protects

Compounds of formula (I): wherein: R is an alkyl group; X is oxygen or sulphur; Y is hydrogen atom or -A-COOH, in which A is an alkylene group; Ar is aryl or substituted aryl group; and pharmaceutically acceptable salts and esters thereof, have use in the treatment or pr…

USPTO Abstract

Compounds of formula (I): wherein: R is an alkyl group; X is oxygen or sulphur; Y is hydrogen atom or -A-COOH, in which A is an alkylene group; Ar is aryl or substituted aryl group; and pharmaceutically acceptable salts and esters thereof, have use in the treatment or prophylaxis of diabetes, obesity, hyperlipaemia, hyperglycaemia, complications of diabetes, obesity-related hypertension and osteoporosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP0590793A1
Jurisdiction
EP
Classification
—
Expires
1994-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Sankyo Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.